Apply to trial NCT07616440

A few quick questions so the study team can decide if you might be a fit.

RecruitingDevice study

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

This study aimed to evaluate the feasibility and safety, and to observe early efficacy signals of the focused ultrasound mediated drug delivery system combined with SonoVue® in patients with HER2-positive breast cancer receiving neoadjuvant therapy by comparing its pathological complete response (pCR) rate with a matched historical cohort of HER2-positive breast cancer patients treated at our center.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening